3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Lymphoma
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Pain, Postoperative
1
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Malignant Neoplasms of Male Genital Organs
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Leukemia
1
Hodgkin Disease
1
Goiter
1
Carcinoma, Small Cell
1
Interventions
vandetanib
7
Sorafenib
6
Magnetic Resonance Spectroscopy
6
lenvatinib
5
cabozantinib
5
Sunitinib
4
Iodine-131
4
selpercatinib
3
AZD 6244
3
trametinib
2
tipifarnib
2
durvalumab
2
dabrafenib
2
alectinib
2
Triiodothyronine
2
Thyroxine
2
Thyrotropin Alfa
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Everolimus
2
Bortezomib
2
Axitinib
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
tremelimumab
1
temsirolimus
1
tanespimycin
1
sapanisertib
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Thyroid Neoplasms
×
Epinephrine
×
Clear all
NCT02112370
2017-08-04
REBT
Seoul National University Hospital
Phase 3
Completed
148 enrolled
17 charts